Spore-FP1
Spore-FP1 is a subunit vaccine candidate consisting of inactivated Bacillus subtilis spores coated with the FP1 fusion protein and formulated with Poly(I:C) adjuvant. FP1 fusion protein comprises Ag85B, Acr/HspX and the N-terminal domain of HBHA antigen. It is intended as a mucosal boost vaccine in BCG-immunised hosts.
Read MoreH107e/CAF10b
H107e/CAF®10b is being developed by SSI and is a next-generation TB subunit vaccine incorporating 8 different Mtb antigens in a novel liposomal Th1/Th17 inducing adjuvant. It is specifically designed to complement a BCG response with novel T cells against Mtb-specific antigens and comes with the option of BCG co-administration.
Read MoreSpray Dried ID93+GLA-SE
AAHI’s tuberculosis vaccine candidate includes a recombinant fusion subunit protein antigen, ID93, formulated with GLA-SE, a squalene emulsion containing the synthetic Toll-like receptor 4 agonist glucopyranosyl lipid A (GLA). The vaccine candidate was developed on AAHI’s formulation (adjuvant and delivery vehicle) vaccine platform.
Read MoreM72/AS01E
The M72/AS01E vaccine candidate consists of the M72 fusion protein and the proprietary GSK adjuvant system AS01E.
Read MoreGamTBvac
GamTBvac is a recombinant vaccine containing three Mycobacterium tuberculosis (MTB) antigens: Ag85a and ESAT6-CFP10 fusion protein, fused with a dextran-binding domain (DBD) from Leuconostoc mesenteroides. These fusions are formulated with the adjuvant containing Dextran 500 kDa and DEAE-Dextran 500 kDa covered with CpG oligonucleotides.
Read More